Table 3.
Mean Deviation in Test Results in Samples With Low and High DOAC Concentrations
| Samples <60 ng/mL | Samples ≥60 ng/mL | All Samples | |
|---|---|---|---|
| Dabigatran | |||
| HTI | 12.3±25.2 ng/mL | −2.6±44.1 ng/mL | 8.2±32.0 ng/mL |
| 95% CI [8.0, 16.6] | 95% CI [−14.9, 9.7] | 95% CI [3.5, 12.9] | |
| BDTI | −3.1±10.2 ng/mL | −2.9±24.9 ng/mL | −1.4±15.8 ng/mL |
| 95% CI [−4.9, −1.3] | 95% CI [−9.9, 4.1] | 95% CI [−3.7, 0.9] | |
| ECT | 4.3±7.8 ng/mL | 13.6±30.6 ng/mL | 6.9±17.8 ng/mL |
| 95% CI [3.0, 5.6] | 95% CI [5.0, 22.2] | 95% CI [4.3, 9.5] | |
| Rivaroxaban | |||
| Calibrated AXA | −2.9±18.5 ng/mL | −10.2±32.9 ng/mL | −7.7±29.0 ng/mL |
| 95% CI [−8.0, 2.2] | 95% CI [−16.8, −3.6] | 95% CI [−12.4, −3.0] | |
| Apixaban | |||
| Calibrated AXA | −12.3±14.7 ng/mL | −7.7±28.8 ng/mL | −10.2±22.2 ng/mL |
| 95% CI [−15.4, −9.2] | 95% CI [−14.4, −1.0] | 95% CI [−13.7, −6.7] | |
Samples=178 (dabigatran), 146 (rivaroxaban), 157 (apixaban). Values±SD. AXA indicates anti‐Xa activity; BDTI, Biophen direct thrombin inhibitor assay; CI, confidence interval; DOAC, direct oral anticoagulants; ECT, ecarin clotting time; HTI, Hemoclot direct thrombin inhibitor assay.